COVID-19 vaccination in autoimmune disease (COVAD) survey protocol

COVAD Study Group

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.

Original languageEnglish
Pages (from-to)23-29
Number of pages7
JournalRheumatology International
Volume42
Issue number1
DOIs
Publication statusPublished - 2022 Jan

Keywords

  • Autoimmune diseases
  • COVAD
  • COVID-19
  • Survey
  • Vaccination

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'COVID-19 vaccination in autoimmune disease (COVAD) survey protocol'. Together they form a unique fingerprint.

Cite this